Homburger advised and represented Bristol-Myers Squibb in its acquisition of Celgene

On November 20, 2019, Bristol-Myers Squibb Company (Bristol-Myers Squibb) announced that it had completed its acquisition of Celgene Corporation following the receipt of regulatory approval from all government authorities required by the merger agreement as well as approval by Bristol-Myers Squibb and Celgene stockholders. The cash and stock transaction had an equity value of approximately USD 74 bn.

Homburger AG advised Bristol-Myers Squibb on all competition law matters and represented the company in the merger control proceedings in Switzerland. The Homburger team was led by partner Marcel Dietrich and comprised counsel Andreas Burger and Associate Allegra Arnold (all Competition, Regulatory).